Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Therapeutische Umschau. Revue Therapeutique|December 1, 1990
[Clinical experiences with femovan (Gynera)]K Brill, B Düsterberg, M Albring
Advances in Contraception : the Official Journal of the Society for the Advancement of Contraception|December 1, 1990
Clinical experience with a low-dose oral contraceptive containing gestodeneB Düsterberg, K Brill
American Journal of Obstetrics and Gynecology|October 1, 1990
Clinical acceptability of monophasic gestodeneB Düsterberg, K Brill
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|December 1, 1990
Long-term experience with a low-dose oral contraceptiveK Brill, J Schnitker, M Albring
Annales D'Endocrinologie|October 16, 1999
[The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type]H Gollnick, M Albring, K Brill
Advances in Contraception : the Official Journal of the Society for the Advancement of Contraception|December 1, 1994
Clinical experience with a modern low-dose gestodene-containing oral contraceptive in adolescentsK Brill, J Schnitker, M Albring
Contraception|February 1, 1991
Clinical experience with a modern low-dose oral contraceptive in almost 100,000 usersK Brill, T Norpoth, J Schnitker, et al.
European Journal of Endocrinology|September 2, 1998
Gestodene and desogestrel do not have a different influence on concentration profiles of ethinylestradiol in women taking oral contraceptives--results of isotope dilution mass spectrometry measurementsL Siekmann, A Siekmann, F Bidlingmaier, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|December 1, 1995
The influence of the dose of ethinylestradiol in oral contraceptives on follicle growthA T Teichmann, K Brill, M Albring, et al.
Contraception|January 23, 1998
A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cyclesR Bannemerschult, J P Hanker, C Wünsch, et al.
Pageof 8